

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q

(Mark One)

- ☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the quarterly period ended March 31, 2024
- OR
- ☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the transition period from _ to _
Commission File Number: 001-38753



Moderna, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware 81-3467528
(State or Other Jurisdiction of Incorporation or (IRS Employer
Organization) Identification No.)

325 Binney Street
Cambridge, Massachusetts 02142
(Address of Principal Executive Offices) (Zip Code)

(617) 714-6500
(Registrant's Telephone Number, Including Area Code)

200 Technology Square, Cambridge, Massachusetts 02139
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	MRNA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. **Yes** ☒ **No** ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). **Yes** ☒ **No** ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). **Yes** ☐ **No** ☒

As of April 26, 2024, there were 383,239,726 shares of the registrant's common stock, par value \$0.0001 per share, outstanding.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (Form 10-Q) contains express or implied forward-looking statements. All statements other than those of historical facts contained in this Form 10-Q are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements in this Form 10-Q include, but are not limited to, statements about:

- our activities with respect to our COVID-19 vaccine, and our plans and expectations regarding future generations of our COVID-19 vaccine that we may develop, including in response to variants of the SARS-CoV-2 virus, ongoing clinical development, manufacturing and supply, pricing, commercialization, regulatory matters (including authorization or approval for updated vaccines), demand for COVID-19 vaccines, our provisions for product returns, and third-party and governmental arrangements and potential arrangements;
 - our expectations regarding the endemic and seasonal commercial market for COVID-19 vaccines and our preparations for and ability to effectively compete in such a market, as well as the impact that the evolving market will have on our financial returns;
 - expected sales and delivery of our COVID-19 vaccine in future periods, and expected seasonality for sales;
 - mRNA-1283's design to be refrigerator-stable and its potential for paving the way for a combination vaccine;
 - our expectations regarding regulatory approvals for our respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345), and the U.S. ACIP recommendation in 2024, and plans for commercialization of this product;
 - our financing arrangement with Blackstone Life Sciences, and other funding options we may consider as part of our research and development strategy;
 - our ability to successfully contract with third-party suppliers, distributors and manufacturers;
 - our ability and the ability of third parties with whom we contract to successfully manufacture, supply and distribute our COVID-19 vaccine and any future commercial products at scale, as well as drug substances, delivery vehicles, development candidates, and investigational medicines for preclinical and clinical use;
 - internal and external costs associated with manufacturing our products, including our COVID-19 vaccine, and the impact on our cost of sales, and our anticipated 2024 cost of sales as a percentage of net product sales;
 - the scope of protection we are able to establish and maintain for intellectual property rights covering our commercial products, product candidates and technology, including our ability to enter into license agreements, and our expectations regarding pending legal proceedings related to our intellectual property;
 - the potential of our individualized neoantigen therapy (INT) program and our plans for the program, including to expand to additional tumor types;
 - the timing of initiation, progress, completion, results and cost of our clinical trials, preclinical studies and research and development programs, as well as those of our collaborators;
 - participant enrollment in our clinical trials, including enrollment demographics and timing;
 - potential advantages of mRNA as compared to traditional medicine;
 - our ability to obtain and maintain regulatory approval of our product candidates;
 - the implementation of our business model and strategic plans for our business, products, product candidates and technology;
 - potential product launches, including the timing of launches;
 - our ability to successfully commercialize our products, if approved;
 - the pricing and reimbursement of our medicines, if approved;
 - the build out of our manufacturing and commercial operations;
-

- estimates of our future expenses, revenues and capital requirements;
- our operation and funding requirements, including our forecast of the period of time through which our financial resources will be adequate to support our operations;
- the potential benefits of strategic collaboration agreements and our ability to enter into strategic collaborations or other agreements with collaborators with development, regulatory and commercialization expertise;
- our financial performance;
- our tax provision and related tax liabilities;
- legal and regulatory developments in the United States and foreign countries;
- our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost; and
- developments relating to our competitors and our industry.

Forward-looking statements often contain words such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our operational or financial performance, and involve risks, uncertainties, and other factors that may cause our actual results to differ materially from any future results expressed or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled “Risk Factors” and elsewhere in this Form 10-Q and under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual results could differ materially from those expressed or implied by the forward-looking statements.

The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We undertake no obligation to update any forward-looking statements, except as required by applicable securities law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q. However, any further disclosures made on related subjects in our subsequent reports filed with the Securities and Exchange Commission should be consulted.

TRADEMARKS

This Form 10-Q contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to may appear without the ® or ™ symbols, but such references are not intended to indicate that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our reference to other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

NOTE REGARDING COMPANY REFERENCES

Unless the context otherwise requires, the terms “Moderna,” the “Company,” “we,” “us” and “our” in this Form 10-Q refer to Moderna, Inc. and its consolidated subsidiaries.

ADDITIONAL INFORMATION

Our website, www.modernatx.com, including the Investor Relations section, www.investors.modernatx.com; and corporate blog www.modernatx.com/moderna-blog, and our Statements and Perspectives webpage, <https://investors.modernatx.com/Statements--Perspectives/default.aspx>; as well as our social media channels: Facebook, www.facebook.com/modernatx; X, [@moderna_tx](https://www.twitter.com/moderna_tx); LinkedIn, www.linkedin.com/company/modernatx; Instagram ([@moderna_tx](https://www.instagram.com/moderna_tx)); and Threads ([@moderna_tx](https://www.threads.net/@moderna_tx)) contain a significant amount of information about us, including financial and other information for investors. We encourage investors to visit these websites and social media channels as information is frequently updated and new information is shared. Information contained on our website, corporate blog and social media channels shall not be deemed incorporated into, or be a part of, this Form 10-Q.

Table of Contents

	Page
PART I.	
Item 1.	<u>Financial Statements (Unaudited)</u> <u>5</u>
	<u>Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023</u> <u>5</u>
	<u>Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023</u> <u>6</u>
	<u>Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2024 and 2023</u> <u>7</u>
	<u>Condensed Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2024 and 2023</u> <u>8</u>
	<u>Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023</u> <u>9</u>
	<u>Notes to Condensed Consolidated Financial Statements</u> <u>10</u>
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> <u>25</u>
Item 3.	<u>Quantitative and Qualitative Disclosures about Market Risk</u> <u>33</u>
Item 4.	<u>Controls and Procedures</u> <u>33</u>
PART II.	
Item 1.	<u>Legal Proceedings</u> <u>34</u>
Item 1A.	<u>Risk Factors</u> <u>34</u>
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u> <u>34</u>
Item 6.	<u>Exhibits</u> <u>35</u>
SIGNATURES	<u>36</u>

Item 1. Financial Statements

MODERNA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in millions, except per share data)

	March 31, 2024	December 31, 2023
Assets		
Current assets:		
Cash and cash equivalents	\$ 2,051	\$ 2,907
Investments	6,472	5,697
Accounts receivable, net	137	892
Inventory	295	202
Prepaid expenses and other current assets	645	627
Total current assets	9,600	10,325
Investments, non-current	3,638	4,677
Property, plant and equipment, net	2,063	1,945
Right-of-use assets, operating leases	697	713
Deferred tax assets	81	81
Other non-current assets	650	685
Total assets	<u>\$ 16,729</u>	<u>\$ 18,426</u>
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 183	\$ 520
Accrued liabilities	1,396	1,798
Deferred revenue	559	568
Income taxes payable	52	63
Other current liabilities	190	66
Total current liabilities	2,380	3,015
Deferred revenue, non-current	58	83
Operating lease liabilities, non-current	637	643
Financing lease liabilities, non-current	575	575
Other non-current liabilities	262	256
Total liabilities	3,912	4,572
Commitments and contingencies (Note 11)		
Stockholders' equity:		
Preferred stock, par value \$0.0001; 162 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023	—	—
Common stock, par value \$0.0001; 1,600 shares authorized as of March 31, 2024 and December 31, 2023; 383 and 382 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	—	—
Additional paid-in capital	487	371
Accumulated other comprehensive loss	(101)	(123)
Retained earnings	12,431	13,606
Total stockholders' equity	12,817	13,854
Total liabilities and stockholders' equity	<u>\$ 16,729</u>	<u>\$ 18,426</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MODERNA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in millions, except per share data)

	Three Months Ended March 31,	
	2024	2023
Revenue:		
Net product sales	\$ 167	\$ 1,828
Other revenue	—	34
Total revenue	167	1,862
Operating expenses:		
Cost of sales	96	792
Research and development	1,063	1,131
Selling, general and administrative	274	305
Total operating expenses	1,433	2,228
Loss from operations	(1,266)	(366)
Interest income	120	109
Other expense, net	(19)	(48)
Loss before income taxes	(1,165)	(305)
Provision for (benefit from) income taxes	10	(384)
Net (loss) income	\$ (1,175)	\$ 79
(Loss) earnings per share:		
Basic	\$ (3.07)	\$ 0.20
Diluted	\$ (3.07)	\$ 0.19
Weighted average common shares used in calculation of (loss) earnings per share:		
Basic	382	386
Diluted	382	405

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MODERNA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited, in millions)

	Three Months Ended March 31,	
	2024	2023
Net (loss) income	\$ (1,175)	\$ 79
Other comprehensive (loss) income, net of tax:		
Available-for-sale securities:		
Unrealized gains on available-for-sale debt securities	20	79
Less: net realized losses on available-for-sale securities reclassified in net (loss) income	2	16
Net increase from available-for-sale debt securities	22	95
Cash flow hedges:		
Unrealized gains on derivative instruments	—	—
Less: net realized losses on derivative instruments reclassified in net (loss) income	—	8
Net increase from derivatives designated as hedging instruments	—	8
Total other comprehensive income	22	103
Comprehensive (loss) income	\$ (1,153)	\$ 182

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MODERNA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited, in millions)

	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings	Total Stockholders' Equity
	Shares	Amount				
Balance at December 31, 2023	382	\$ —	\$ 371	\$ (123)	\$ 13,606	\$ 13,854
Exercise of options to purchase common stock	1	—	15	—	—	15
Stock-based compensation	—	—	101	—	—	101
Other comprehensive income, net of tax	—	—	—	22	—	22
Net loss	—	—	—	—	(1,175)	(1,175)
Balance at March 31, 2024	383	\$ —	\$ 487	\$ (101)	\$ 12,431	\$ 12,817

	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings	Total Stockholders' Equity
	Shares	Amount				
Balance at December 31, 2022	385	\$ —	\$ 1,173	\$ (370)	\$ 18,320	\$ 19,123
Vesting of restricted common stock	1	—	—	—	—	—
Exercise of options to purchase common stock	2	—	9	—	—	9
Stock-based compensation	—	—	75	—	—	75
Other comprehensive income, net of tax	—	—	—	103	—	103
Repurchase of common stock	(4)	—	(526)	—	—	(526)
Net income	—	—	—	—	79	79
Balance at March 31, 2023	384	\$ —	\$ 731	\$ (267)	\$ 18,399	\$ 18,863

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MODERNA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in millions)

	Three Months Ended March 31,	
	2024	2023
Operating activities		
Net (loss) income	\$ (1,175)	\$ 79
Adjustments to reconcile net (loss) income to net cash used in operating activities:		
Stock-based compensation	101	75
Depreciation and amortization	36	78
Amortization/accretion of investments	(27)	(17)
Loss on equity investments, net	13	18
Deferred income taxes	—	(310)
Other non-cash items	3	(4)
Changes in assets and liabilities, net of acquisition of business:		
Accounts receivable, net	755	272
Prepaid expenses and other assets	3	(212)
Inventory	(93)	216
Right-of-use assets, operating leases	16	4
Accounts payable	(303)	(117)
Accrued liabilities	(398)	(495)
Deferred revenue	(33)	(819)
Income taxes payable	(11)	18
Operating lease liabilities	(6)	4
Other liabilities	130	(15)
Net cash used in operating activities	(989)	(1,225)
Investing activities		
Purchases of marketable securities	(2,544)	(1,085)
Proceeds from maturities of marketable securities	1,573	1,360
Proceeds from sales of marketable securities	1,285	1,957
Purchases of property, plant and equipment	(196)	(113)
Acquisition of business, net of cash acquired	—	(85)
Investment in convertible notes and equity securities	—	(23)
Net cash provided by investing activities	118	2,011
Financing activities		
Proceeds from issuance of common stock through equity plans	15	9
Repurchase of common stock, including excise tax	—	(526)
Changes in financing lease liabilities	(1)	(25)
Net cash provided by (used in) financing activities	14	(542)
Net (decrease) increase in cash, cash equivalents and restricted cash	(857)	244
Cash, cash equivalents and restricted cash, beginning of year	2,928	3,217
Cash, cash equivalents and restricted cash, end of period	\$ 2,071	\$ 3,461
Non-cash investing and financing activities		
Purchases of property and equipment included in accounts payable and accrued liabilities	\$ 91	\$ 98
Right-of-use assets obtained through finance lease modifications and reassessments	\$ —	\$ (60)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MODERNA, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Description of the Business

Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with our strategic collaborators.

Our COVID-19 vaccine is our first commercial product and is marketed, where approved, under the name Spikevax[®]. Our original vaccine, mRNA-1273, targeted the SARS-CoV-2 ancestral strain, and we have leveraged our mRNA platform to rapidly adapt our vaccine to emerging SARS-CoV-2 strains to provide protection as the virus evolves and regulatory guidance is updated.

We have a diverse and extensive development pipeline of 40 development candidates across our 47 development programs, of which 43 are in clinical studies currently.

2. Summary of Basis of Presentation and Recent Accounting Standards

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2023 (2023 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the audited consolidated financial statements in our 2023 Form 10-K.

The condensed consolidated financial statements include Moderna, Inc. and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The significant accounting policies used in the preparation of these condensed consolidated financial statements for the three months ended March 31, 2024 are consistent with those described in our 2023 Form 10-K. The only exception pertains to the policy related to research and development funding. We entered into a research and development funding arrangement in the first quarter of 2024. Please refer to Note 5 for further details regarding this policy. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the operating results to be expected for the full fiscal year or future operating periods. We anticipate seasonal fluctuations in demand for our COVID-19 vaccine, with higher sales expected during the fall and winter seasons.

Use of Estimates

We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.

Comprehensive Income (Loss)

Comprehensive income (loss) includes net income (loss) and other comprehensive income/loss for the period. Other comprehensive income/loss consists of unrealized gains/losses on our investments, derivatives designated as hedging instruments, and pension and postretirement obligation adjustments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).

The components of accumulated other comprehensive loss for the three months ended March 31, 2024 were as follows (in millions):

	Unrealized Gains on Available-for-Sale Debt Securities	Pension and Postretirement Benefits	Total
Accumulated other comprehensive loss, balance at December 31, 2023	\$ (114)	\$ (9)	\$ (123)
Other comprehensive income	22	—	22
Accumulated other comprehensive loss, balance at March 31, 2024	<u>\$ (92)</u>	<u>\$ (9)</u>	<u>\$ (101)</u>

Restricted Cash

We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows.

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):

	March 31,	
	2024	2023
Cash and cash equivalents	\$ 2,051	\$ 3,441
Restricted cash ⁽¹⁾	17	—
Restricted cash, non-current ⁽²⁾	3	20
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	<u>\$ 2,071</u>	<u>\$ 3,461</u>

⁽¹⁾Included in prepaid expenses and other current assets in the condensed consolidated balance sheets.

⁽²⁾Included in other non-current assets in the condensed consolidated balance sheets.

Recently Issued Accounting Standards Not Yet Adopted

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU broadens the disclosure requirements by requiring disclosures of significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss. The standard also requires entities to disclose, on an interim and annual basis, the amount and description, including the nature and type, of the other segment items. Additionally, entities are required to disclose the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment's profit or loss in assessing segment performance and deciding how to allocate resources. These enhanced disclosure obligations apply to entities that operate with one reportable segment as well. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. Early adoption is permitted. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statement disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as additional information on income taxes paid. The standard requires entities to disclose federal, state, and foreign income taxes in their rate reconciliation tables and elaborate on reconciling items that exceed a quantitative threshold. Additionally, it requires an annual disclosure of income taxes paid, net of refunds, categorized by jurisdiction based on a quantitative threshold. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statement disclosures.

3. Net Product Sales

Net product sales by customer geographic location were as follows (in millions):

	Three Months Ended March 31,	
	2024	2023
United States	\$ 100	\$ 1
Europe	—	576
Rest of world	67	1,251
Total	<u>\$ 167</u>	<u>\$ 1,828</u>

As of March 31, 2024, our COVID-19 vaccine was our only commercial product authorized for use.

Prior to the third quarter of 2023, we sold our COVID-19 vaccine to the U.S. Government, foreign governments and international organizations. The agreements and related amendments with these entities generally do not include variable consideration, such as discounts, rebates or returns. Certain of these agreements entitle us to upfront deposits for our COVID-19 vaccine supply, initially recorded as deferred revenue.

As of March 31, 2024 and December 31, 2023, we had deferred revenue of \$580 million and \$613 million, respectively, related to customer deposits for our COVID-19 vaccine. We expect \$522 million of our deferred revenue related to customer deposits as of March 31, 2024 to be realized in less than one year. Timing of product delivery and manufacturing, and receipt of marketing approval for the applicable COVID-19 vaccine will determine the period in which product sales are recognized.

In the third quarter of 2023, we commenced sales of our latest COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and international organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us.

Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions.

The following table summarizes product sales provision for the periods presented (in millions):

	Three Months Ended March 31,	
	2024	2023
Gross product sales	\$ 222	\$ 1,828
Product sales provision:		
Wholesaler chargebacks, discounts and fees	(22)	—
Returns and other fees	(33)	—
Total product sales provision	<u>\$ (55)</u>	<u>\$ —</u>
Net product sales	<u>\$ 167</u>	<u>\$ 1,828</u>

The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the three months ended March 31, 2024 (in millions):

	Returns and other fees	
Balance at December 31, 2023	\$	(556)
Provision related to sales made in current period		(33)
Payments and returns related to sales made in prior periods		15
Balance at March 31, 2024	\$	(574)

4. Other Revenue

The following table summarizes other revenue for the periods presented (in millions):

	Three Months Ended March 31,	
	2024	2023
Grant revenue	\$ —	\$ 24
Collaboration revenue	—	10
Total other revenue	\$ —	\$ 34

Grant revenue and collaboration revenue were immaterial for the three months ended March 31, 2024.

Grant Revenue

In April 2020, we entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for an award of up to \$483 million to accelerate development of mRNA-1273. The agreement has been subsequently amended to provide for additional commitments to support various late-stage clinical development efforts of our original COVID-19 vaccine, mRNA-1273, including a 30,000 participant Phase 3 study, pediatric clinical trials, adolescent clinical trials and pharmacovigilance studies. The maximum award from BARDA, inclusive of all amendments, was approximately \$1.8 billion. All contract options have been exercised. As of March 31, 2024, the remaining available funding, net of revenue earned was \$101 million.

5. Collaboration Agreements and Research and Development Funding Arrangement

Merck

In June 2016, we entered into a Collaboration and License Agreement for the development and commercialization of personalized mRNA cancer vaccines (also known as individualized neoantigen therapy, or INT) with Merck. This agreement was subsequently amended and restated in 2018. Our role in this strategic alliance involves identifying genetic mutations in a particular patient's tumor cells, synthesizing mRNA for these mutations, encapsulating the mRNA in one of our proprietary lipid nanoparticles (LNPs), and administering a unique mRNA INT to each patient. Each INT is designed to specifically activate the patient's immune system against her or his own cancer cells.

In September 2022, Merck exercised its option for INT, including mRNA-4157, pursuant to the terms of the agreement and in October 2022 paid us an option exercise fee of \$250 million. Following this exercise, the Merck Participation Term commenced. Pursuant to the agreement, we and Merck have agreed to collaborate on further development and commercialization of INT, with costs and any profits or losses to be shared equally on a worldwide basis.

For the three months ended March 31, 2024 and 2023, we recognized expenses of \$76 million and \$19 million, respectively, net of Merck's reimbursements, related to the INT collaboration under the Merck Participation Term. Additionally, for the three months ended March 31, 2024 and 2023, the net cost recovery for capital expenditures was \$24 million and \$6 million, respectively, which was applied to reduce the capitalized cost of the asset.

We have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events have occurred. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized.

Development and Commercialization Funding Arrangement with Blackstone Life Sciences (Blackstone)

In March 2024, we entered into a development and commercialization funding arrangement with Blackstone, under which Blackstone commits to providing up to \$750 million in funding to us. This funding will support the development of our investigational mRNA-based influenza vaccine. Contingent upon regulatory approval in the U.S. and only if the approval is dependent on data from the funded activities, Blackstone will be entitled to receive low single-digit percentage royalties and up to \$750 million in sales milestone payments. These payments are based on net sales of our future influenza and combination vaccines, with sales milestone payments contingent upon achieving specified cumulative net sales targets.

Given the substantive transfer of financial risk to Blackstone, we account for this arrangement as an obligation to conduct research and development activities. The funding will be recognized as a reduction to the expenses of our mRNA-based influenza program. This reduction will be recognized proportionally as the related costs are incurred, based on an input method. No expense reduction associated with this arrangement was recorded in the first quarter of 2024.

6. Financial Instruments

Cash and Cash Equivalents and Investments

The following tables summarize our cash and available-for-sale securities by significant investment category as of March 31, 2024 and December 31, 2023 (in millions):

March 31, 2024							
	Amortized Cost	Unrealized Gains	Unrealized Losses	Estimated Fair Value	Cash and Cash Equivalents	Current Marketable Securities	Non-Current Marketable Securities
Cash and cash equivalents	\$ 2,051	\$ —	\$ —	\$ 2,051	\$ 2,051	\$ —	\$ —
Available-for-sale:							
Certificates of deposit	75	—	—	75	—	75	—
U.S. treasury bills	1,157	—	—	1,157	—	1,157	—
U.S. treasury notes	3,873	1	(56)	3,818	—	2,445	1,373
Corporate debt securities	4,901	2	(65)	4,838	—	2,639	2,199
Government debt securities	226	—	(4)	222	—	156	66
Total	<u>\$ 12,283</u>	<u>\$ 3</u>	<u>\$ (125)</u>	<u>\$ 12,161</u>	<u>\$ 2,051</u>	<u>\$ 6,472</u>	<u>\$ 3,638</u>
December 31, 2023							
	Amortized Cost	Unrealized Gains	Unrealized Losses	Estimated Fair Value	Cash and Cash Equivalents	Current Marketable Securities	Non-Current Marketable Securities
Cash and cash equivalents	\$ 2,907	\$ —	\$ —	\$ 2,907	\$ 2,907	\$ —	\$ —
Available-for-sale:							
Certificates of deposit	27	—	—	27	—	27	—
U.S. treasury bills	807	—	—	807	—	807	—
U.S. treasury notes	4,407	3	(67)	4,343	—	2,664	1,679
Corporate debt securities	5,067	3	(81)	4,989	—	2,082	2,907
Government debt securities	211	—	(3)	208	—	117	91
Total	<u>\$ 13,426</u>	<u>\$ 6</u>	<u>\$ (151)</u>	<u>\$ 13,281</u>	<u>\$ 2,907</u>	<u>\$ 5,697</u>	<u>\$ 4,677</u>

The amortized cost and estimated fair value of available-for-sale securities by contractual maturity as of March 31, 2024 and December 31, 2023 were as follows (in millions):

	March 31, 2024	
	Amortized Cost	Estimated Fair Value
Due in one year or less	\$ 6,536	\$ 6,472
Due after one year through five years	3,696	3,638
Total	<u>\$ 10,232</u>	<u>\$ 10,110</u>

	December 31, 2023	
	Amortized Cost	Estimated Fair Value
Due in one year or less	\$ 5,751	\$ 5,697
Due after one year through five years	4,768	4,677
Total	<u>\$ 10,519</u>	<u>\$ 10,374</u>

In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive income (loss), net of applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did not recognize any impairment charges related to available-for-sale securities for the three months ended March 31, 2024 and 2023. We did not record any credit-related allowance to available-for-sale securities as of March 31, 2024 and December 31, 2023.

The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by the length of time the securities have been in an unrealized loss position as of March 31, 2024 and December 31, 2023 (in millions):

	Less than 12 Months		12 Months or More		Total	
	Gross Unrealized Losses	Estimated Fair Value	Gross Unrealized Losses	Estimated Fair Value	Gross Unrealized Losses	Estimated Fair Value
As of March 31, 2024:						
U.S. treasury bills	\$ —	\$ 947	\$ —	\$ —	\$ —	\$ 947
U.S. treasury notes	(7)	1,603	(49)	2,025	(56)	3,628
Corporate debt securities	(4)	1,068	(62)	2,929	(66)	3,997
Government debt securities	—	51	(3)	145	(3)	196
Total	<u>\$ (11)</u>	<u>\$ 3,669</u>	<u>\$ (114)</u>	<u>\$ 5,099</u>	<u>\$ (125)</u>	<u>\$ 8,768</u>
As of December 31, 2023:						
U.S. treasury bills	\$ —	\$ 25	\$ —	\$ —	\$ —	\$ 25
U.S. treasury notes	(3)	774	(64)	2,983	(67)	3,757
Corporate debt securities	(1)	562	(79)	3,518	(80)	4,080
Government debt securities	—	8	(4)	143	(4)	151
Total	<u>\$ (4)</u>	<u>\$ 1,369</u>	<u>\$ (147)</u>	<u>\$ 6,644</u>	<u>\$ (151)</u>	<u>\$ 8,013</u>

As of March 31, 2024 and December 31, 2023, we held 395 and 392 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments, nor do we believe that we are more-likely-than-not to conclude we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:

- Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
- Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or
- Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2024 and December 31, 2023 (in millions):

	Fair value at March 31, 2024	Fair Value Measurement Using	
		Level 1	Level 2
Assets:			
Money market funds	\$ 709	\$ 709	\$ —
Certificates of deposit	75	—	75
U.S. treasury bills	2,158	—	2,158
U.S. treasury notes	3,818	—	3,818
Corporate debt securities	5,072	—	5,072
Government debt securities	222	—	222
Equity investments ⁽¹⁾	53	53	—
Derivative instruments	3	—	3
Total	<u>\$ 12,110</u>	<u>\$ 762</u>	<u>\$ 11,348</u>
	Fair value at December 31, 2023	Fair Value Measurement Using	
		Level 1	Level 2
Assets:			
Money market funds	\$ 1,572	\$ 1,572	\$ —
Certificates of deposit	27	—	27
U.S. treasury bills	1,246	—	1,246
U.S. treasury notes	4,343	—	4,343
Corporate debt securities	5,480	—	5,480
Government debt securities	208	—	208
Equity Investments ⁽¹⁾	24	24	—
Derivative instruments	4	—	4
Total	<u>\$ 12,904</u>	<u>\$ 1,596</u>	<u>\$ 11,308</u>
Liabilities:			
Derivative instruments	\$ 9	\$ —	\$ 9

⁽¹⁾Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense, net, in our condensed consolidated statements of operations.

As of March 31, 2024 and December 31, 2023, we did not have non-financial assets or liabilities measured at fair value on a recurring basis and did not have any Level 3 financial assets or financial liabilities.

For the three months ended March 31, 2024 and 2023, we recognized net losses of \$13 million and \$18 million on equity investments from changes in fair value of the securities.

In addition, as of December 31, 2023, we had \$42 million in equity investments without readily determinable fair values, which were recorded within other non-current assets in our condensed consolidated balance sheets and excluded from the fair value measurement tables above. These investments became publicly traded during the first quarter of 2024 and were recorded at their quoted market price in our condensed consolidated balance sheets as of March 31, 2024.

7. Inventory

Inventory as of March 31, 2024 and December 31, 2023 consisted of the following (in millions):

	March 31, 2024	December 31, 2023
Raw materials	\$ 215	\$ 163
Work in progress	60	15
Finished goods	20	24
Total inventory	<u>\$ 295</u>	<u>\$ 202</u>
Inventory, non-current ⁽¹⁾	\$ 145	\$ 170

⁽¹⁾Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the condensed consolidated balance sheets.

Inventory write-downs as a result of excess, obsolescence, scrap or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our condensed consolidated statements of operations. For the three months ended March 31, 2024 and 2023, inventory write-downs were \$30 million and \$148 million, respectively. For the three months ended March 31, 2024, there were no losses on firm purchase commitments. For the three months ended March 31, 2023, losses on firm purchase commitments were \$66 million. Inventory write-downs were mainly related to obsolete inventory due to shelf-life expiration and inventory in excess of expected demand. Losses on firm purchase commitments were primarily related to excess raw material purchase commitments that will expire before the anticipated consumption of those raw materials.

As of March 31, 2024 and December 31, 2023, the accrued liability for losses on firm future purchase commitments in our condensed consolidated balance sheets was \$24 million and \$79 million, respectively. As of March 31, 2024 and December 31, 2023, we had inventory on hand of \$440 million and \$372 million, respectively. Our raw materials and work-in-progress inventory have variable shelf lives. We expect that the majority of this inventory will be consumed over the next three years. The shelf life of our COVID-19 vaccine product ranges from nine to twelve months.

8. Property, Plant and Equipment, Net

Property, plant and equipment, net, as of March 31, 2024 and December 31, 2023 consisted of the following (in millions):

	March 31, 2024	December 31, 2023
Land and land improvements	\$ 32	\$ 22
Manufacturing and laboratory equipment	355	345
Leasehold improvements	642	522
Furniture, fixtures and other	32	26
Computer equipment and software	73	74
Construction in progress	865	860
Right-of-use assets, financing (Note 10)	529	529
Total	2,528	2,378
Less: Accumulated depreciation	(465)	(433)
Property, plant and equipment, net	<u>\$ 2,063</u>	<u>\$ 1,945</u>

Depreciation and amortization expense for three months ended March 31, 2024 and 2023 was \$35 million and \$78 million, respectively.

9. Other Balance Sheet Components

Accounts Receivable, net

Accounts receivable, net, as of March 31, 2024 and December 31, 2023 consisted of the following (in millions):

	March 31, 2024	December 31, 2023
Accounts receivable	\$ 422	\$ 1,584
Less: Wholesalers chargebacks, discounts and fees	(285)	(692)
Accounts receivable, net	<u>\$ 137</u>	<u>\$ 892</u>

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets, as of March 31, 2024 and December 31, 2023 consisted of the following (in millions):

	March 31, 2024	December 31, 2023
Prepaid services	\$ 204	\$ 182
Down payments and prepayments related to manufacturing and materials	123	168
Income tax receivable	93	19
Interest receivable	62	59
Collaboration receivable	59	61
Value added tax receivable	36	50
Other current assets	68	88
Prepaid expenses and other current assets	<u>\$ 645</u>	<u>\$ 627</u>

Other Non-Current Assets

Other non-current assets, as of March 31, 2024 and December 31, 2023 consisted of the following (in millions):

	March 31, 2024	December 31, 2023
Down payments and prepayments, non-current	\$ 322	\$ 342
Inventory, non-current ⁽¹⁾	145	170
Equity investments	53	66
Goodwill	52	52
Finite-lived intangible asset	43	44
Other	35	11
Other non-current assets	<u>\$ 650</u>	<u>\$ 685</u>

⁽¹⁾Consisted of raw materials with an anticipated consumption beyond one year.

Accrued Liabilities

Accrued liabilities, as of March 31, 2024 and December 31, 2023 consisted of the following (in millions):

	March 31, 2024	December 31, 2023
Provisions related to product sales (Note 3)	\$ 574	\$ 556
Development operations	141	140
Clinical trials	136	175
Other external goods and services	135	137
Manufacturing	112	167
Compensation-related	95	245
Property, plant and equipment	95	94
Commercial	40	56
Raw materials	36	27
Loss on future firm purchase commitments ⁽¹⁾	24	79
Royalties	8	122
Accrued liabilities	<u>\$ 1,396</u>	<u>\$ 1,798</u>

⁽¹⁾Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases ([Note 7](#)).

Other Current Liabilities

Other current liabilities, as of March 31, 2024 and December 31, 2023 consisted of the following (in millions):

	March 31, 2024	December 31, 2023
Lease liabilities - operating (Note 10)	\$ 25	\$ 25
Estimated reimbursements to wholesalers and distributors	119	—
Other	46	41
Other current liabilities	<u>\$ 190</u>	<u>\$ 66</u>

Deferred Revenue

The following table summarizes the activities in deferred revenue for the three months ended March 31, 2024 (in millions):

	December 31, 2023	Additions	Deductions	March 31, 2024
Product sales	\$ 613	\$ 14	\$ (47)	\$ 580
Grant revenue	4	—	—	4
Collaboration revenue	34	3	(4)	33
Total deferred revenue	<u>\$ 651</u>	<u>\$ 17</u>	<u>\$ (51)</u>	<u>\$ 617</u>

10. Leases

We have entered into various long-term, non-cancelable lease arrangements for our facilities and equipment, expiring at various times through 2042. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease costs under such arrangements on a straight-line basis over the life of the lease. We have two main campuses in Massachusetts, our Cambridge campus and our Moderna Technology Center (MTC), an industrial technology center located in Norwood. We also lease various parcels of land, and office and lab spaces across the globe for our business operations.

Cambridge Campus

Our Cambridge campus consists of multiple leased properties, including office and research laboratory spaces totaling approximately 276,000 square feet, exclusive of the Moderna Science Center.

Moderna Science Center

In September 2021, we entered into a lease agreement for a building in Cambridge Massachusetts, comprising approximately 462,000 square feet. This facility, which includes our principal executive offices along with additional office and laboratory spaces, is referred to as the Moderna Science Center (MSC). After an approximately two-year building project, the lease term is 15 years, with options for two additional seven-year extensions. During the third quarter of 2023, we commenced the lease and recognized the related right-of-use asset and lease liability on our condensed consolidated balance sheets. Following the commencement of the MSC lease, we amended the expiration dates of our existing leases at Technology Square in the fourth quarter of 2023. Originally scheduled to expire ranging from 2024 to 2029, these leases have been adjusted to conclude in early 2025. All our Cambridge leases are classified as operating leases.

Moderna Technology Center

Our Moderna Technology Center is composed of three buildings, MTC South, MTC North and MTC East, totaling approximately 686,000 square feet. Our MTC leases expire in 2042 and we have the option to extend the term for three extension periods of five years each. All of our MTC leases are classified as finance leases.

Operating and financing lease right-of-use assets and lease liabilities as of March 31, 2024 and December 31, 2023 were as follows (in millions):

	March 31, 2024	December 31, 2023
Assets:		
Right-of-use assets, operating, net ^{(1) (2)}	\$ 697	\$ 713
Right-of-use assets, financing, net ^{(3) (4)}	433	436
Total	<u>\$ 1,130</u>	<u>\$ 1,149</u>
Liabilities:		
Current:		
Operating lease liabilities ⁽⁵⁾	\$ 25	\$ 25
Total current lease liabilities	25	25
Non-current:		
Operating lease liabilities, non-current	637	643
Financing lease liabilities, non-current	575	575
Total non-current lease liabilities	<u>1,212</u>	<u>1,218</u>
Total	<u>\$ 1,237</u>	<u>\$ 1,243</u>

⁽¹⁾These assets are real estate related assets, which include land, office, and laboratory spaces.

⁽²⁾Net of accumulated amortization.

⁽³⁾These assets are real estate assets related to the MTC leases.

⁽⁴⁾Included in property, plant and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.

⁽⁵⁾Included in other current liabilities in the condensed consolidated balance sheets.

Future minimum lease payments under our non-cancelable lease agreements as of March 31, 2024, were as follows (in millions):

Fiscal Year	Operating Leases	Financing Leases ⁽¹⁾
2024 (remainder of the year)	\$ 55	\$ 14
2025	67	22
2026	67	22
2027	70	23
2028	72	23
Thereafter	784	1,074
Total minimum lease payments	<u>1,115</u>	<u>1,178</u>
Less amounts representing interest or imputed interest	<u>(453)</u>	<u>(603)</u>
Present value of lease liabilities	<u>\$ 662</u>	<u>\$ 575</u>

⁽¹⁾Includes certain optional lease term extensions, predominantly related to the MTC leases, which represent a total of \$668 million of undiscounted future lease payments.

11. Commitments and Contingencies

Legal Proceedings

We are involved in various claims and legal proceedings of a nature considered ordinary course in our business. The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment. We are not currently a party to any legal proceedings for which a material loss is probable, or for which a loss is reasonably estimable at this time.

Indemnification Obligations

As permitted under Delaware law, we indemnify our officers, directors, and employees for certain events, occurrences while the officer, or director is, or was, serving at our request in such capacity. The term of the indemnification is for the officer's or director's lifetime.

We have standard indemnification arrangements in our leases for laboratory and office space that require us to indemnify the landlord against any liability for injury, loss, accident, or damage from any claims, actions, proceedings, or costs resulting from certain acts, breaches, violations, or non-performance under our leases.

We enter into indemnification provisions under our agreements with counterparties in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited.

Through the three months ended March 31, 2024 and the year ended December 31, 2023, we had not experienced any material losses related to these indemnification obligations, and no material claims were outstanding. We do not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.

Purchase Commitments and Purchase Orders

We enter into agreements in the normal course of business with vendors and contract manufacturing organizations for raw materials and manufacturing services and with vendors for preclinical research studies, clinical trials and other goods or services. As of March 31, 2024, we had \$1.8 billion of non-cancelable purchase commitments related to raw materials and manufacturing agreements, which are expected to be paid through 2029. As of March 31, 2024, \$24 million of the purchase commitments related to raw materials was recorded as an accrued liability for loss on future firm purchase commitments. As of March 31, 2024, we had \$223 million of non-cancelable purchase commitments related to clinical services and other goods and services which are expected to be paid through 2039. These amounts represent our minimum contractual obligations, including termination fees.

In addition to purchase commitments, we have agreements with third parties for various goods and services, including services related to clinical operations and support and contract manufacturing, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or winddown costs. Under such agreements, we are contractually obligated to make certain payments to vendors, mainly, to reimburse them for their unrecoverable outlays incurred prior to cancellation. As of March 31, 2024, we had cancelable open purchase orders of \$2.6 billion in total under such agreements for our significant clinical operations and support and contract manufacturing. These amounts represent only our estimate of those items for which we had a contractual commitment to pay as of March 31, 2024, assuming we would not cancel these agreements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.

Licenses to Patented Technology

We have patent license agreements with Cellscript, LLC and its affiliate, mRNA RiboTherapeutics, Inc., and the National Institute of Allergy and Infectious Diseases. Under these agreements, we are required to pay royalties and certain milestone payments. For further information on our licensing and royalty payments, please refer to our 2023 Form 10-K under the heading "Business—Intellectual Property—In-licensed intellectual property" and Note 11 to our consolidated financial statements contained therein.

For the three months ended March 31, 2024 and 2023, we recognized \$8 million and \$86 million, respectively, of royalty expenses associated with our product sales. These royalty expenses were recorded to cost of sales in our condensed consolidated statements of operations.

Additionally, we have other in-license agreements with third parties which require us to make future development, regulatory and commercial milestone payments and sales-based royalties for specified products associated with the agreements. The achievement of these milestones have not yet occurred as of March 31, 2024.

12. Stock-Based Compensation and Share Repurchase Programs

Stock-Based Compensation

The following table presents the components and classification of stock-based compensation expense for the three months ended March 31, 2024 and 2023 as follows (in millions):

	Three Months Ended March 31,	
	2024	2023
Options	\$ 40	\$ 36
Restricted Stock Units (RSUs) and Performance Stock Units (PSUs)	58	37
Employee Stock Purchase Plan (ESPP)	3	2
Total	\$ 101	\$ 75
Cost of sales	\$ 7	\$ 5
Research and development	60	42
Selling, general and administrative	34	28
Total	\$ 101	\$ 75

As of March 31, 2024, there was \$1.2 billion of total unrecognized compensation cost related to unvested stock-based compensation with respect to options, RSUs and PSUs granted. That cost is expected to be recognized over a weighted-average period of 2.9 years as of March 31, 2024.

Share Repurchase Programs

As of March 31, 2024, \$1.7 billion of our Board of Directors' authorization for repurchases of our common stock (the 2022 Repurchase Programs) remains outstanding, with no expiration date. The timing and actual number of shares repurchased under the 2022 Repurchase Programs will depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

During the three months ended March 31, 2024, there were no shares repurchased.

13. Income Taxes

The following table summarizes our income tax expense for the periods presented (in millions, except for percentages):

	Three Months Ended March 31,	
	2024	2023
Loss before income taxes	\$ (1,165)	\$ (305)
Provision for (benefit from) income taxes	\$ 10	\$ (384)
Effective tax rate	(0.9)%	125.9 %

The effective tax rate for the three months ended March 31, 2024 was higher than the statutory rate, due to certain of our foreign subsidiaries that have taxable income, while we incurred a net loss before income taxes on a consolidated basis. We cannot recognize tax benefits from the loss due to our global valuation allowance, which we continue to maintain against the majority of our global deferred tax assets. The change in our effective tax rate, compared to the same period in 2023, primarily results from the continued application of our valuation allowance and adjustments of our valuation allowance, which was initially established in the third quarter of 2023. For additional details regarding our deferred tax assets and the policies governing our valuation allowance, please refer to Note 13 to our consolidated financial statements in our 2023 Form 10-K.

We periodically reassess the need for valuation allowances on our deferred tax assets, considering both positive and negative evidence to evaluate whether it is more likely than not that all or a portion of such assets will not be realized. Significant management judgment is required in assessing the realizability of our deferred tax assets. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to modify our valuation allowance, which could materially impact our financial position and results of operations.

We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We are not currently subject to any tax assessment from an income tax examination in the U.S. or any other major taxing jurisdiction.

14. (Loss) Earnings per Share

The computation of basic (loss) earnings per share (EPS) is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and potential dilutive common shares during the period as determined by using the treasury stock method.

Basic and diluted EPS for the three months ended March 31, 2024 and 2023 were calculated as follows (in millions, except per share data):

	Three Months Ended March 31,	
	2024	2023
<i>Numerator:</i>		
Net (loss) income	\$ (1,175)	\$ 79
<i>Denominator:</i>		
Basic weighted-average common shares outstanding	382	386
Effect of dilutive securities	—	19
Diluted weighted-average common shares outstanding	382	405
Basic EPS	\$ (3.07)	\$ 0.20
Diluted EPS	\$ (3.07)	\$ 0.19
Anti-dilutive potential common shares excluded from the EPS computation above	35	5

2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited financial information and related notes included in this Form 10-Q and our consolidated financial statements and related notes and other financial information in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission (the SEC) on February 23, 2024 (the 2023 Form 10-K).

Overview

We are a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with our strategic collaborators.

Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio and integrated manufacturing capabilities that allow for rapid clinical and commercial production at scale. We have a diverse and extensive development pipeline of 40 development candidates across our 47 development programs, of which 43 are in clinical studies currently.

Our COVID-19 vaccine is our first commercial product and is marketed, where approved, under the name Spikevax[®]. Our original vaccine, mRNA-1273, targeted the SARS-CoV-2 ancestral strain, and we have leveraged our mRNA platform to rapidly adapt our vaccine to emerging SARS-CoV-2 strains to provide protection as the virus evolves and regulatory guidance is updated.

Business Highlights

Research and development continues to be our top capital allocation priority. As we look to create value through our research and development strategy for our mRNA portfolio, we are taking three prioritization parameters into consideration: pipeline advancement, revenue diversification and risk reduction. As part of our strategy, the funding options we consider are self-funding, project financing and partnerships.

In March 2024, we entered into a development and commercialization funding agreement with Blackstone Life Sciences to advance our flu program. As part of the agreement, Blackstone will fund up to \$750 million with a return based on cumulative commercial milestones and low-single digit royalties. The funding will be recognized as a reduction to the expenses of our flu program. We will retain full rights and control of our flu program.

In April 2024, we entered a non-exclusive out-licensing agreement with a pharmaceutical company based in Japan for mRNA COVID-19-related intellectual property for the territory of Japan. We will receive an upfront payment of \$50 million, which includes a \$20 million prepayment creditable against future royalties. Additionally, we are entitled to low double-digit royalties on the net sales of the company's COVID-19 product.

Our involvement in our collaboration with Metagenomi was terminated in April 2024. We remain a Metagenomi shareholder.

For the first quarter of 2024, we recognized net product sales of \$167 million from sales of our COVID-19 vaccine, compared to \$1.8 billion for the first quarter of 2023. Diluted loss per share was \$(3.07) for the first quarter of 2024, compared to diluted earnings per share of \$0.19 for the first quarter of 2023.

Recent Program Developments

COVID-19

- We continue to address the needs of the endemic COVID-19 market by focusing on public health efforts to increase vaccination coverage rates to reduce the substantial burden of COVID-19, as well as by advancing next-generation vaccines. Our mRNA platform can produce variant-matched vaccines on an accelerated time horizon, consistent with recent U.S. Food and Drug Administration (FDA) comments on the timing of potential strain selection for the fall 2024 season.
- In March 2024, we announced that our next-generation COVID-19 vaccine (mRNA-1283) had successfully met the primary endpoints of its Phase 3 clinical trial. The positive interim results from the NEXTCove Phase 3 trial showed that mRNA-1283

elicited a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222. mRNA-1283 is designed to be refrigerator-stable and could pave the way for a combination vaccine against influenza and COVID-19 (mRNA-1083). mRNA-1283 is our fourth infectious disease vaccine program with positive Phase 3 data.

Respiratory Syncytial Virus (RSV)

- Our RSV vaccine candidate (mRNA-1345) is in an ongoing Phase 2/3 clinical trial. Based on positive data from the study, we have filed for regulatory approvals for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults over 60 years of age. We are awaiting regulatory approvals and the U.S. Advisory Committee on Immunization Practices (ACIP) recommendation in 2024.
- mRNA-1345 has the potential to protect all vulnerable populations from RSV. We have initiated multiple Phase 3 expansion studies in adults over 50 years of age to evaluate co-administration and re-vaccination. Additional trials (Phase 1 - Phase 3) have been initiated for high-risk adults, as well as maternal and pediatric populations. Interim data from these studies could be available as early as 2024.

Individualized neoantigen therapy (INT)

- We continue to demonstrate the potential clinical benefit of our INT program (mRNA-4157). In partnership with Merck, two Phase 3 trials in resected high-risk (stage III/IV) melanoma and completely resected stage II, IIIA or IIIB non-small cell lung cancer are ongoing.
- We and Merck have initiated three new randomized clinical studies in additional tumor types in 2024, including a Phase 2 adjuvant treatment in patients with renal cell carcinoma, or kidney cancer; a Phase 2 adjuvant treatment in patients with high-risk muscle-invasive bladder cancer; and a Phase 2/3 neoadjuvant and adjuvant treatment in patients with cutaneous squamous cell carcinoma, the second most common form of skin cancer.

Latent and Other Vaccines

- *Epstein-Barr virus (EBV)*: Our EBV vaccine candidate for the prevention of infectious mononucleosis (mRNA-1189) showed positive immunogenicity and safety data in a Phase 1 study. We are advancing mRNA-1189 toward pivotal development.
- *Varicella-Zoster virus (VZV) vaccine*: In a Phase 1/2 trial, our VZV vaccine candidate for the prevention of shingles (mRNA-1468) elicited comparable or higher T cell responses relative to Shingrix. We are advancing toward a pivotal Phase 3 trial.
- *Norovirus*: Our vaccine candidate for the prevention of norovirus (mRNA-1403) showed positive immunogenicity and safety data in a Phase 1 study. We are advancing toward a pivotal Phase 3 trial.

Rare Disease and Other Therapeutics

- *Propionic Acidemia (PA)*: In April 2024, interim data for the first-in-human, Phase 1/2, open-label, dose optimization study and extension study, evaluating the safety and efficacy of our investigational mRNA therapy for PA (mRNA-3927), were published in *Nature*. These interim data indicate early signs of potential clinical benefit with mRNA-3927, and also demonstrate that mRNA-3927 has infrequent treatment-limiting side effects.
- *PD-L1 therapeutic*: Following a strategic review, and as a result of our decision to prioritize investments in other programs, we are discontinuing development of our preclinical PD-L1 program (mRNA-6981), and are no longer evaluating other mRNA candidates in this area.

Our Pipeline

The following chart shows our current pipeline of 47 development programs across our six modalities.

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
 Infectious disease vaccines	COVID-19 vaccine	mRNA-1273/Spikevax®						Worldwide
	COVID-19 vaccine (next generation)	mRNA-1283						Worldwide
	Flu vaccine	mRNA-1010						Worldwide
		mRNA-1020						Worldwide
		mRNA-1030						Worldwide
		mRNA-1011						Worldwide
		mRNA-1012						Worldwide
	Older adults RSV vaccine	mRNA-1345						Worldwide
	Flu + COVID vaccine	mRNA-1083						Worldwide
	Flu + COVID + RSV vaccine	mRNA-1230						Worldwide
	Flu + RSV vaccine	mRNA-1045						Worldwide
	Endemic HCoV vaccine	mRNA-1287						Worldwide
	Pandemic Flu	mRNA-1018						Worldwide
	RSV + hMPV vaccine	mRNA-1365						Worldwide
	COVID-19 vaccine (adolescents)	mRNA-1273.815						Worldwide
	COVID-19 vaccine (pediatrics)	mRNA-1273.815						Worldwide
	Pediatric RSV vaccine	mRNA-1345						Worldwide
	CMV vaccine	mRNA-1647						Worldwide
	EBV vaccine (to prevent IM)	mRNA-1189						Worldwide
	EBV vaccine (to prevent EBV sequelae)	mRNA-1195						Worldwide
	HSV vaccine	mRNA-1608						Worldwide
 Latent vaccines	VZV vaccine	mRNA-1468						Worldwide
	HIV vaccines	mRNA-1644						Worldwide IAVI funded
		mRNA-1574						Worldwide IAVI/others funded
	Enteric	Norovirus vaccines	mRNA-1403					Worldwide
		mRNA-1405						Worldwide
	Bacterial	Lyme vaccines	mRNA-1975					Worldwide
		mRNA-1982						Worldwide
	Public health vaccines	Zika vaccine	mRNA-1893					Worldwide BARDA funded
		Nipah vaccine	mRNA-1215					Worldwide NIH funded
		Mpox vaccine	mRNA-1769					Worldwide
 Cancer vaccines & therapeutics	Individualized neoantigen therapy (INT) – adjuvant melanoma	mRNA-4157						50-50 global profit sharing with Merck
	Individualized neoantigen therapy (INT) – adjuvant NSCLC	mRNA-4157						50-50 global profit sharing with Merck
	Individualized neoantigen therapy (INT) – cSCC	mRNA-4157						50-50 global profit sharing with Merck
	Individualized neoantigen therapy (INT) – RCC	mRNA-4157						50-50 global profit sharing with Merck
	Individualized neoantigen therapy (INT) – bladder cancer	mRNA-4157						50-50 global profit sharing with Merck
	KRAS vaccine	mRNA-5671						Worldwide
	Checkpoint vaccine	mRNA-4359						Worldwide
	OX40L/IL-23/IL-36γ (Triplet) Solid tumors/lymphoma	mRNA-2752						Worldwide
	Propionic acidemia (PA)	mRNA-3927						Worldwide
	Methylmalonic acidemia (MMA)	mRNA-3705						Worldwide
 Rare disease intracellular therapeutics	Glycogen storage disease type 1a (GSD1a)	mRNA-3745						Worldwide
	Ornithine transcarbamylase deficiency (OTC)	mRNA-3139						Worldwide
	Phenylketonuria (PKU)	mRNA-3210						Worldwide
	Crigler-Najjar syndrome type I (CN-I)	mRNA-3351						Provided to ILCM free of charge
	Cystic fibrosis (CF)	mRNA-3692 / VX-522						Verlex to pay milestones and royalties
	Relaxin Heart failure	mRNA-0184						Worldwide
 Inhaled pulmonary therapeutics								
 Systemic secreted & cell surface therapeutics								

Abbreviations: BARDA, Biomedical Advanced Research and Development Authority; CMV, cytomegalovirus; cSCC, cutaneous squamous cell carcinoma; EBV, Epstein-Barr virus; HCoV, human coronaviruses; HIV, human immunodeficiency virus; hMPV, human metapneumovirus; HSV, herpes simplex virus; IAVI, International AIDS Vaccine Initiative; ILCM, Institute for Life Changing Medicines; IL-23, interleukin 23; IL-36γ, interleukin-36 gamma; IM, infectious mononucleosis; NIH, National Institutes of Health; NSCLC, non-small cell lung cancer; OX40L, wildtype OX40 ligand; RCC, renal cell carcinoma; RSV, respiratory syncytial virus; VZV, varicella-zoster virus.

Results of operations

The following table summarizes our condensed consolidated statements of operations for the periods presented (in millions):

	Three Months Ended March 31,		Change 2024 vs. 2023	
	2024	2023	\$	%
Revenue:				
Net product sales	\$ 167	\$ 1,828	\$ (1,661)	(91)%
Other revenue	—	34	(34)	(100)%
Total revenue	167	1,862	(1,695)	(91)%
Operating expenses:				
Cost of sales	96	792	(696)	(88)%
Research and development	1,063	1,131	(68)	(6)%
Selling, general and administrative	274	305	(31)	(10)%
Total operating expenses	1,433	2,228	(795)	(36)%
Loss from operations	(1,266)	(366)	(900)	246%
Interest income	120	109	11	10%
Other expense, net	(19)	(48)	29	(60)%
Loss before income taxes	(1,165)	(305)	(860)	282%
Provision for (benefit from) income taxes	10	(384)	394	(103)%
Net (loss) income	\$ (1,175)	\$ 79	\$ (1,254)	(1,587)%

Revenue

Net product sales

Net product sales by customer geographic location were as follows (in millions):

	Three Months Ended March 31,	
	2024	2023
United States	\$ 100	\$ 1
Europe	—	576
Rest of world	67	1,251
Total	\$ 167	\$ 1,828

In the third quarter of 2023, we commenced sales of our COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and international organizations. In the U.S., our COVID-19 vaccine is now sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns, and other related deductions.

The following table summarizes product sales provision for the periods presented (in millions):

	Three Months Ended March 31,	
	2024	2023
Gross product sales	\$ 222	\$ 1,828
Product sales provision:		
Wholesaler chargebacks, discounts and fees	(22)	—
Returns and other fees	(33)	—
Total product sales provision	\$ (55)	\$ —
Net product sales	\$ 167	\$ 1,828

As of March 31, 2024, our COVID-19 vaccine was our only commercial product authorized for use.

As of March 31, 2024, we had deferred revenue of \$580 million associated with customer deposits received or billable under supply agreements, with the majority of our COVID-19 vaccine deliveries scheduled in 2024.

Our net product sales for the first quarter of 2024 declined significantly as compared to the first quarter of 2023. This decline is indicative of the evolving nature of the endemic COVID-19 vaccine market, which has transitioned toward a seasonal commercial pattern. The sales in the first quarter reflect this greater seasonality, with reduced demand observed during this period. We anticipate that the demand for our COVID-19 vaccine will be higher in the fall and winter seasons across both hemispheres, as countries prepare for seasonal vaccination campaigns. For the full year of 2024, we expect the progression toward a seasonal commercial market to persist, resulting in further projected reductions in net product sales for our COVID-19 vaccine relative to 2023.

Other revenue

Other revenue comprises grant revenue and collaboration revenue, which were immaterial for the three months ended March 31, 2024.

Total revenue decreased by \$1.7 billion, or 91%, for the three months ended March 31, 2024, compared to the same period in 2023, mainly due to a reduction in net product sales of our COVID-19 vaccine.

Net product sales decreased by \$1.7 billion, or 91%, for the three months ended March 31, 2024, compared to the same period in 2023. This was primarily due to lower sales volumes in regions outside the United States, coupled with the market's transition to a seasonal commercial pattern for the COVID-19 vaccine market. Additionally, the decrease in sales volume was attributed to the fact that in the prior year period, we primarily delivered doses that had been deferred from 2022. This decline was partially offset by a higher average selling price, particularly in the United States, where commercial market sales commenced in the third quarter of 2023.

Other revenue decreased by \$34 million, or 100%, for the three months ended March 31, 2024, compared to the same period in 2023, mainly due to a reduction in grant revenue under our agreement with BARDA for the development of our COVID-19 vaccine.

Operating expenses

Cost of sales

Cost of sales for the three months ended March 31, 2024 was \$96 million, which include third-party royalties of \$8 million, inventory write-downs of \$30 million, and unutilized manufacturing capacity and winddown costs of \$27 million. Cost of sales for the three months ended March 31, 2023 was \$792 million, including third-party royalties of \$86 million, inventory write-downs of \$148 million, unutilized manufacturing capacity of \$135 million, and losses on firm purchase commitments and related cancellation fees of \$95 million. Please refer to [Note 7](#) to our condensed consolidated financial statements for inventory related charges. These charges in 2024, other than royalties, were largely attributable to end-of-season demand adjustments and commitments related to manufacturing capacity.

Cost of sales for the three months ended March 31, 2024 decreased by \$696 million, or 88%, compared to the same period in 2023. Cost of sales as a percentage of net product sales for the three months ended March 31, 2024 was 58%, compared to 43% for the same period in 2023. The decrease in cost of sales in 2024 was primarily driven by lower sales volume coupled with reduced unutilized manufacturing capacity, inventory write-downs and losses on firm purchase commitments and related cancellation fees. Conversely, the increase in cost of sales as a percentage of net product sales in 2024 was mainly due to the low level of net product sales compared to the prior year, reflecting a decline in product demand and increased product seasonality.

Despite the increase in the cost of sales as a percentage of net product sales in the first quarter of 2024 compared to the same period in 2023, we anticipate that the full year cost of sales as a percentage of net product sales for 2024 will be lower than the 70% experienced in 2023. This expectation is based on projected improvements in our manufacturing efficiency and expected reductions in inventory write-downs. However, due to the strong seasonality of our business, we expect this percentage to be higher in the first half of the year than the second half of the year.

Research and development expenses

Research and development expenses decreased by \$68 million, or 6%, for the three months ended March 31, 2024, compared to the same period in 2023. The decrease was primarily attributable to a reduction in upfront license payments of \$85 million. Additionally, there were decreases in manufacturing costs for clinical trial materials of \$44 million and clinical trial expenses of \$35 million, largely driven by lower clinical development spending on our COVID-19, RSV and seasonal flu programs. These reductions were partially offset by an increase in personnel-related costs and stock-based compensation of \$54 million, mainly driven by an increased headcount in the research and development functions.

We anticipate a modest reduction in research and development expenses in 2024 compared to 2023 levels. We continue to advance the development of variant-specific and next-generation COVID-19 vaccine candidates, and continue to develop our pipeline and advance our product candidates into later-stage development, in particular those in ongoing Phase 3 studies, including our RSV, seasonal flu, CMV and combination vaccine programs, as well as our INT program.

Selling, general and administrative expenses

Selling, general and administrative expenses decreased by \$31 million, or 10%, for the three months ended March 31, 2024, compared to the same period in 2023. The decrease was mainly due to an \$80 million reduction in consulting and outside services across all functions. This decrease was partially offset by an increase in personnel-related costs and stock-based compensation of \$31 million, primarily driven by an expanded headcount in digital, medical affairs and commercial functions to support our digital and artificial intelligence initiatives and marketed products.

We anticipate that selling, general and administrative expenses in 2024 will be slightly lower than the levels experienced in 2023. This reflects our ongoing commitment to efficiency as we expand our global commercial, regulatory, sales and marketing infrastructure. Moreover, it aligns with our strategic focus on advancing our program development and enhancing our overall business processes.

Interest income

Interest income increased by \$11 million, or 10%, for the three months ended March 31, 2024, compared to the same period in 2023. The increase in interest income from our investments in marketable securities for the three month period in 2024 was mainly attributable to an overall higher interest rate environment, partially offset by lower average investment balances.

Other expense, net

The following tables summarize other expense, net for the periods presented (in millions):

	Three Months Ended March 31,		Change 2024 vs. 2023	
	2024	2023	\$	%
Loss on investments	\$ (15)	\$ (35)	\$ 20	(57)%
Interest expense	(6)	(9)	3	(33)%
Other income (expense), net	2	(4)	6	150%
Total other expense, net	<u>\$ (19)</u>	<u>\$ (48)</u>	<u>\$ 29</u>	<u>(60)%</u>

Total other expense, net decreased by \$29 million, or 60%, for the three months ended March 31, 2024, compared to the same period in 2023. The decrease in other expense, net for the three months ended March 31, 2024 was primarily due to decreases in losses on available-for-sale debt securities and equity investments. Our interest expense is primarily related to our finance leases. Please refer to [Note 10](#) to our condensed consolidated financial statements.

Income taxes

We had a tax provision of \$10 million for the three months ended March 31, 2024. Provision for income taxes increased by \$394 million, or 103%, for the three months ended March 31, 2024, compared to the same period in 2023, primarily due to certain of our foreign subsidiaries that have taxable income, while we incurred a net loss before income taxes on a consolidated basis. We cannot recognize tax benefits from the loss due to our global valuation allowance, which we continue to maintain against the majority of our global deferred tax assets. As a result of the valuation allowance, the effective tax rate for the three months ended March 31, 2024 is not comparable to the same period in prior year. Please refer to [Note 13](#) to our condensed consolidated financial statements.

Liquidity and capital resources

The following table summarizes our cash, cash equivalents, investments and working capital as of March 31, 2024 and December 31, 2023 (in millions):

	March 31, 2024	December 31, 2023
Financial assets:		
Cash and cash equivalents	\$ 2,051	\$ 2,907
Investments	6,472	5,697
Investments, non-current	3,638	4,677
Total	\$ 12,161	\$ 13,281
Working capital:		
Current assets	\$ 9,600	\$ 10,325
Current liabilities	2,380	3,015
Total	\$ 7,220	\$ 7,310

Our cash, cash equivalents and investments are invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Investments, consisting primarily of government and corporate debt securities, are stated at fair value. Cash, cash equivalents and investments as of March 31, 2024 decreased by \$1.1 billion, or 8%, compared to December 31, 2023. During the three months ended March 31, 2024, we had a net cash outflow from operating activities of \$989 million and purchases of property and equipment of \$196 million.

Working capital, which is current assets less current liabilities, as of March 31, 2024 decreased by \$90 million, or 1%, compared to December 31, 2023, primarily due to a decrease in accounts receivable of \$755 million mainly due to timing of collections, and an increase in other current liabilities of \$124 million driven by estimated reimbursements to wholesalers for wholesaler chargebacks. This was partially offset by a decrease in accrued liabilities of \$402 million and a decrease in accounts payable of \$337 million, both of which were driven by lower spend in manufacturing and development.

As of March 31, 2024, we did not have any off-balance sheet arrangements, other than those obligations and commitments disclosed herein.

Cash flow

The following table summarizes the primary sources and uses of cash for each period presented (in millions):

	Three Months Ended March 31,	
	2024	2023
Net cash (used in) provided by:		
Operating activities	\$ (989)	\$ (1,225)
Investing activities	118	2,011
Financing activities	14	(542)
Net (decrease) increase in cash, cash equivalents and restricted cash	\$ (857)	\$ 244

Operating activities

We derive cash flows from operations primarily from cash collected from customer deposits and accounts receivable related to our COVID-19 vaccine product sales, as well as certain government-sponsored and private organizations, strategic alliances and funding arrangements. Our cash flows from operating activities are significantly affected by our use of cash for operating expenses and working capital to support the business.

Beginning in the third quarter of 2020, we entered into supply agreements with the U.S. Government, foreign governments and international organizations for the supply of our COVID-19 vaccine and received upfront deposits. In the third quarter of 2023, we commenced sales of our COVID-19 vaccine to the U.S. commercial market, in addition to continuing sales to foreign governments and international organizations. In the U.S., our COVID-19 vaccine is sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us. As of March 31, 2024, we had \$580 million in deferred revenue related to customer deposits received or billable.

Net cash used in operating activities for the three months ended March 31, 2024 was \$989 million and consisted of net loss of \$1.2 billion, a net change in assets and liabilities, net of acquisition of business, of \$60 million and non-cash adjustments of \$126 million. Non-cash items primarily included stock-based compensation of \$101 million, and depreciation and amortization of \$36 million. The net change in assets and liabilities was mainly due to a decrease in accounts receivable of \$755 million driven by timing of collections, and an increase in other liabilities of \$130 million mainly due to estimated reimbursements to wholesalers for wholesaler chargebacks, partially offset by a decrease in accrued liabilities of \$398 million and a decrease in accounts payable of \$303 million, driven by overall lower spending in manufacturing and development.

Net operating cash flows increased by \$236 million, or 19%, during the three months ended March 31, 2024, compared to the same period in 2023, primarily attributable to a change in deferred revenue of \$786 million due to revenue recognized from deferred revenue in excess of customer deposits received, accounts receivable of \$483 million related to timing of collections, deferred income taxes of \$310 million driven by an increase in valuation allowance, and prepaid expenses and other assets of \$215 million driven by a decrease in vendor prepayments and down payments, partially offset by a decrease in net income of \$1.3 billion.

Investing activities

Our primary investing activities consist of purchases, sales, and maturities of our investments, capital expenditures for land, building, leasehold improvements, manufacturing, laboratory, computer equipment and software, and business development.

Net cash provided by investing activities for the three months ended March 31, 2024 was \$118 million, which primarily included proceeds from maturities and sales of marketable securities of \$2.9 billion, partially offset by purchases of marketable securities of \$2.5 billion, and purchases of property and equipment of \$196 million.

Net investing cash flows decreased by \$1.9 billion, or 94%, during the three months ended March 31, 2024, compared to the same period in 2023, primarily due to an increase in purchases of marketable securities of \$1.5 billion, and a decrease in proceeds from sale of marketable securities of \$672 million.

Financing activities

Net cash provided by financing activities for the three months ended March 31, 2024 was \$14 million, primarily due to proceeds from issuance of common stock through equity plans of \$15 million.

Net cash provided by financing activities increased by \$556 million, or 103%, during the three months ended March 31, 2024, compared to the same period in 2023, mainly due to a decrease in repurchases of common stock.

Operation and funding requirements

Our principal sources of funding as of March 31, 2024 consisted of cash and cash equivalents, investments, and cash we may generate from operations. We generated net income of \$8.4 billion and \$12.2 billion for the years ended in 2022 and 2021, respectively, following the authorization of our first commercial product in December 2020. From our inception to the end of 2020, we incurred significant losses from operations due to our significant research and development expenses. We also incurred a net loss of \$1.2 billion for the three months ended March 31, 2024 and a net loss of \$4.7 billion for the year ended in 2023. We have retained earnings of \$12.4 billion as of March 31, 2024.

We have significant future capital requirements including expected operating expenses to conduct research and development activities, operate our organization, and meet capital expenditure needs. We anticipate maintaining substantial expenses across all areas of our ongoing activities, particularly as we continue research and development of our development candidates and clinical activities for our investigational medicines. This also extends to our manufacturing costs, including our arrangements with our supply and manufacturing partners. Our ongoing work on our RSV, seasonal flu and CMV vaccine candidates, individualized neoantigen therapy, COVID-19 vaccines, including development of any new vaccines against variants of SARS-CoV-2, combination vaccines, late-stage clinical development, and buildout of global commercial, regulatory, sales and marketing infrastructure and manufacturing facilities will require significant cash outflows in future periods, most of which will not be reimbursed or otherwise paid for by our partners or collaborators. In addition, we have substantial facility, lease and purchase obligations (refer to [Note 10](#) and [Note 11](#) to our condensed consolidated financial statements). We have entered into various collaboration and licensing agreements, as well as a research and development funding arrangement with third parties. These arrangements collectively encompass the funding of specific research and development activities, with the distinction that under the research and development funding arrangement, we receive funding. However, for all these arrangements, we may be obligated to make potential future milestone and royalty payments.

We believe that our cash, cash equivalents, and investments as of March 31, 2024, together with cash expected to be generated from product sales, will be sufficient to enable us to fund our projected operations and capital expenditures through at least the next 12 months from the issuance of these financial statements included in this Form 10-Q. We are subject to all the risks related to the development and commercialization of novel medicines, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors, which may adversely affect our business. For example, we experienced a decline in customer demand for our COVID-19 vaccine in 2023, and this trend continued into the first quarter of 2024, reflecting the market's ongoing transition to a seasonal commercial pattern in the endemic COVID-19 vaccine market. We foresee that our commitment to investing in our business for future product launches may lead to continued negative cash flows from operations in upcoming periods. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

Critical accounting policies and significant judgments and estimates

There have been no material changes in our critical accounting policies and estimates in the preparation of our condensed consolidated financial statements during the three months ended March 31, 2024 compared to those disclosed in our 2023 Form 10-K.

Contractual Obligations

As of March 31, 2024, other than disclosed within [Note 5](#), [Note 10](#) and [Note 11](#) to our condensed consolidated financial statements, there have been no material changes to our contractual obligations and commitments from those described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2023 Form 10-K.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our market risks, and the way we manage them, are summarized in Part II, Item 7A., “Quantitative and Qualitative Disclosures About Market Risk” of our 2023 Form 10-K. There have been no material changes to our market risk or to our management of such risks for the three months ended March 31, 2024.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2024, which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by a management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II

Item 1. Legal Proceedings

We are involved in various claims and legal proceedings of a nature considered ordinary course in our business, including the intellectual property litigation described in our 2023 Form 10-K under the heading “Legal Proceedings.” Most of the issues raised by these claims are highly complex and subject to substantial uncertainties. For a description of risks relating to these and other legal proceedings we face, see Part I, Item 1A., “Risk Factors,” of our 2023 Form 10-K, including the discussion under the headings entitled “Risks related to our intellectual property” and “Risks related to the manufacturing of our commercial products and product candidates.” The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment.

Item 1A. Risk Factors

Information regarding risk and uncertainties related to our business appears in Part I, Item 1A. “Risk Factors” of our 2023 Form 10-K. There have been no material changes from the risk factors previously disclosed in the 2023 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

On August 1, 2022, our Board of Directors authorized a share repurchase program for our common stock of up to \$3.0 billion, with no expiration date. During the three months ended March 31, 2024, there were no shares repurchased. As of March 31, 2024, \$1.7 billion of our Board of Directors’ authorization for repurchases of our common stock remains outstanding, with no expiration date.

For details about our share repurchase programs, please refer to Note 12 to our consolidated financial statements, as set forth in our 2023 Form 10-K.

Item 6. Exhibits

The Exhibits listed below are filed or incorporated by reference as part of this Form 10-Q.

<u>Exhibit No.</u>	<u>Exhibit Index</u>
3.1	Second Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit 3.2 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on February 23, 2024)
31.1*	Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1+	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Link Document
104*	Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)

* Filed herewith

+ The certification furnished in Exhibit 32.1 hereto is deemed to accompany this Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certification will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MODERNA, INC.

Date:
May 2, 2024

By: /s/ Stéphane Bancel

Stéphane Bancel
Chief Executive Officer and Director
(*Principal Executive Officer*)

Date:
May 2, 2024

By: /s/ James M. Mock

James M. Mock
Chief Financial Officer
(*Principal Financial Officer*)

**CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

CERTIFICATIONS

I, Stéphane Bancel, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Moderna, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 2, 2024

By: /s/ Stéphane Bancel
Stéphane Bancel
Chief Executive Officer
(Principal Executive Officer)

**CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

CERTIFICATIONS

I, James M. Mock, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Moderna, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 2, 2024

By: /s/ James M. Mock
James M. Mock
Chief Financial Officer
(Principal Financial Officer)

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Moderna, Inc. (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Stéphane Bancel, Chief Executive Officer of the Company, and James M. Mock, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 2, 2024

By: /s/ Stéphane Bancel
Stéphane Bancel
Chief Executive Officer
(Principal Executive Officer)

Date: May 2, 2024

By: /s/ James M. Mock
James M. Mock
Chief Financial Officer
(Principal Financial Officer)